Operating income decreased 36.8%
Operating income changed -36.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$20.5B→$13.0B2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →META financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current assets increased 64.0%
Current assets changed +64.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$73.1B→$119.9B4 prior comparisons
Working capital increased 57.3%
Working capital changed +57.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$36.2B→$56.9B4 prior comparisons
Noncurrent long-term debt increased 180.6%
Noncurrent long-term debt changed +180.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$28.8B→$80.9B4 prior comparisons
Trade receivables increased 31.3%
Trade receivables changed +31.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$17.3B→$22.7B4 prior comparisons
Gross margin moved 273 bp lower
Gross margin changed -273 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
82.03%→79.31%2 prior comparisons
Operating margin moved 1997 bp lower
Operating margin changed -1997 basis points from the comparable as-filed period.
40.07%→20.10%2 prior comparisons
Net income increased 264.0%
Net income changed +264.0% from the comparable as-filed period.
$2.7B→$9.9B2 prior comparisons
Revenue increased 26.1%
Revenue changed +26.1% from the comparable as-filed period.
$51.2B→$64.6B2 prior comparisons
Research & development increased 32.4%
Research & development changed +32.4% from the comparable as-filed period.
$15.1B→$20.1B2 prior comparisons
Capex / revenue moved 1580 bp higher
Capex / revenue changed +1580 basis points from the comparable as-filed period.
36.75%→52.54%2 prior comparisons
Capital expenditure increased 80.3%
Capital expenditure changed +80.3% from the comparable as-filed period.
$18.8B→$33.9B2 prior comparisons
Cost of revenue increased 45.2%
Cost of revenue changed +45.2% from the comparable as-filed period.
$9.2B→$13.4B2 prior comparisons
Free-cash-flow proxy decreased 80.6%
Free-cash-flow proxy changed -80.6% from the comparable as-filed period.
$9.0B→$1.7B3 prior comparisons
Operating cash flow increased 24.7%
Operating cash flow changed +24.7% from the comparable as-filed period.
$25.6B→$31.9B3 prior comparisons
Operating margin moved 1214 bp lower
Operating margin changed -1214 basis points from the comparable as-filed period.
43.02%→30.88%2 prior comparisons
Revenue increased 28.0%
Revenue changed +28.0% from the comparable as-filed period.
$47.5B→$60.8B2 prior comparisons
Research & development increased 67.3%
Research & development changed +67.3% from the comparable as-filed period.
$12.9B→$21.7B2 prior comparisons
Current ratio increased 12.8%
Current ratio changed +12.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
1.97→2.234 prior comparisons
Capex / revenue moved 1473 bp higher
Capex / revenue changed +1473 basis points from the comparable as-filed period.
34.81%→49.53%2 prior comparisons
Capital expenditure increased 82.1%
Capital expenditure changed +82.1% from the comparable as-filed period.
$16.5B→$30.1B3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.